Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Foghorn Therapeutics Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 61 | 59 | −2 |
| Shares | 26.9M | 26.2M | −730.8K (−2.7%) |
| Value | $134.6M | $169.0M | +$34.3M (+25.5%) |
New holders (6)
Institutions that held Foghorn Therapeutics Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sio Capital Management, LLC | 121,672 | $784.8K | 0.20% |
| Gsa Capital Partners LLP | 41,295 | $266.0K | 0.02% |
| Alta Wealth Advisors LLC | 30,032 | $193.7K | 0.11% |
| Jane Street Group, LLC | 12,851 | $82.9K | 0.00% |
| Lazard Asset Management LLC | 8,982 | $57.0K | 0.00% |
| Russell Investments Group, Ltd. | 100 | $645 | 0.00% |
Sold out (8)
Institutions that held Foghorn Therapeutics Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Deerfield Management Company, L.P. (Series C) | 777,525 | $3.89M |
| Wade G W & Inc | 107,770 | $539.0K |
| Ikarian Capital, LLC | 15,292 | $76.5K |
| MetLife Investment Management | 11,445 | $57.2K |
| Metropolitan Life Insurance Co | 1,295 | $6.47K |
| China Universal Asset Management Co., Ltd. | 1,073 | $5.37K |
| Advisor Group Holdings, Inc. | 300 | $1.50K |
| Daiwa Securities Group Inc. | 168 | $1.00K |